慢性炎症性脱髄性多発ニューロパチーの市場：治療、診断、エンドユーザー別-2024-2030年の世界予測

慢性炎症性脱髄性多発ニューロパチー市場規模は2023年に23億5,000万米ドルと推計され、2024年には24億9,000万米ドルに達し、CAGR 5.81％で2030年には34億9,000万米ドルに達すると予測されます。

慢性炎症性脱髄性多発ニューロパチー（CIDP）は神経筋疾患または自己免疫疾患で、足と腕の感覚機能の障害によって分類されます。この疾患は、ミエリン鞘としても知られる神経の保護膜を免疫系が誤って攻撃することに起因します。その結果、神経信号の伝導が遅くなり、筋力低下、反射低下、感覚障害を引き起こします。CIDPは慢性疾患であり、患者のQOLに重大な影響を及ぼすため、神経学において最も重要な疾患です。症状の管理と転帰の改善には、迅速な同定と適切な治療介入が極めて重要であり、この衰弱性障害をターゲットとした治療法の継続的な研究開発の重要性が強調されています。神経疾患に対する懸念の高まりと、これらの疾患の治療を支援する政府の好意的な取り組みが、CIDP治療に対する需要を後押ししています。しかし、CIDPに関連する高コストは、メーカーやエンドユーザーにとって重要な課題です。企業は常に研究開発（R&D）に取り組んでおり、このような状況の中で俊敏性を保つために新薬を投入しています。さらに、CIDPの診断と治療における技術革新は患者の予後を改善し、需要を牽引しています。革新的な研究開発には、より効果的で侵襲の少ない治療法の開発、早期かつ正確な発見のための新規診断ツールの開発、新たな治療標的を発見するためのCIDPの遺伝的基盤の探求などが含まれます。

治療CIDP治療におけるヒト免疫グロブリンG静注の使用増加による患者の転帰の改善

慢性炎症性脱髄性多発ニューロパチー（CIDP）管理は、患者のQOLを向上させながら、不適切な免疫反応を抑制するようデザインされた総合的なアプローチを包含します。治療プロトコルの最前線は、免疫系の機能を調整する抗体を供給する免疫グロブリン静注（IVIG）の投与です。炎症を緩和し、免疫系の活力を調整するプレドニゾンなどの副腎皮質ステロイドも同様に重要です。プラズマフェレーシスは、これらの治療に反応しない患者に対して、有害な抗体を除去するための血液浄化を含む代替戦略です。理学療法は、筋力、しなやかさ、操作能力を維持・向上させることを目的とし、CIDPの包括的治療において不可欠な役割を果たします。

エンドユーザー：病院や診療所におけるCIDP治療の可能性を広げ、効果的な治療法をより広く利用できるようにします。

病院は初期診断と治療の重要な施設として登場し、専門的な医療機器と専門知識を必要とする免疫グロブリン（IVIg）静注療法を含む包括的なケアを提供しています。専門クリニックは、CIDPに関する深い知識を持った専門家による継続的な管理と専門的な治療を提供し、集中的なアプローチを提供しています。在宅ケアは、特に皮下免疫グロブリン（SCIg）療法を含む長期的な治療において、継続的なケアを維持するために注目されています。これらの環境はそれぞれ異なる利点を提供し、CIDP患者集団の特定のニーズに対応することで、効果的な治療レジメンへの幅広いアクセスを確保しています。

地域別の洞察

南北アメリカ、特に米国とカナダでは、CIDPに対する認識と診断率が高まっており、効果的な治療に対する需要が高まっています。患者中心のヘルスケアシステムと高い購買力により、革新的な治療法に対する顧客の購買行動は旺盛です。多額の研究開発投資と有利なヘルスケア政策がCIDP市場の成長を支えています。最近のFDAによるCIDP治療薬の承認は、この地域のこの衰弱性疾患への取り組み姿勢を裏付けています。一方、欧州連合（EU）諸国では、CIDPの認知度、診断、治療へのアクセスに関して多様な状況が見られます。EUのヘルスケアシステムは公平なアクセスを優先しており、希少疾患治療を支援するために、CIDPを含む様々な国が異なるモデルを採用しています。最近のEU全体のイニシアチブは、研究の強化、規制経路の合理化、国境を越えたヘルスケア協力の促進に重点を置いており、大陸全体における患者の転帰の改善を目指しています。中国、日本、インドなどのアジア太平洋諸国は、医療支出の増加と診断能力の向上により、CIDP市場において急速に発展しています。日本は先進的なヘルスケア技術を持ち、特許や臨床試験の多さからもわかるように研究に力を入れている地域です。中国とインドは人口が多く、CIDPを含む自己免疫疾患に対する認識が高まっているため、重要な市場です。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは慢性炎症性脱髄性多発ニューロパチー市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、慢性炎症性脱髄性多発ニューロパチー市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.慢性炎症性脱髄性多発ニューロパチー市場の市場規模および予測は？

2.慢性炎症性脱髄性多発ニューロパチー市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.慢性炎症性脱髄性多発ニューロパチー市場の技術動向と規制枠組みは？

4.慢性炎症性脱髄性多発ニューロパチー市場における主要ベンダーの市場シェアは？

5.慢性炎症性脱髄性多発ニューロパチー市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で自己免疫疾患と神経疾患への懸念が高まる
    • 希少疾患に対するヘルスケア費と保険適用範囲の拡大
    • CIDP治療に対する政府の好ましい取り組みと承認
  • 抑制要因
    • CIDP治療に伴う高額な費用
  • 機会
    • CIDPの病態生理を理解し、新しい治療法を開発するための継続的な調査
    • CIDPの診断と治療における継続的な革新により患者の転帰を改善
  • 課題
    • 他の神経筋疾患との症状の類似性による誤診または診断の遅れ
• 市場セグメンテーション分析
  • 治療：CIDP治療におけるヒト静脈内免疫グロブリンGの使用を増やし、患者の転帰を改善する
  • 最終用途：効果的な治療レジメンへのより広範なアクセスを確保するために、病院や診療所におけるCIDP治療の利用可能性を拡大する
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 慢性炎症性脱髄性多発ニューロパチーの市場治療別

• コルチコステロイド
• 静脈内免疫グロブリン（IVIG）
• 理学療法
• 血漿交換

第7章 慢性炎症性脱髄性多発ニューロパチーの市場診断別

• 血液検査と尿検査
• 電気診断検査
• 腰椎穿刺

第8章 慢性炎症性脱髄性多発ニューロパチーの市場：最終用途別

• ホームケア設定
• 病院
• 専門クリニック

第9章 南北アメリカの慢性炎症性脱髄性多発ニューロパチーの市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の慢性炎症性脱髄性多発ニューロパチーの市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの慢性炎症性脱髄性多発ニューロパチーの市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 武田薬品のHYQVIAが欧州委員会によりCIDP患者の維持療法として承認
  • 武田薬品のHYQVIAがCIDP治療薬としてFDAの承認を取得
  • Zai Lab、中国で慢性炎症性脱髄性多発ニューロパチー患者に対するエフガルチギモドアルファ注射剤（皮下注射剤）の画期的治療薬指定を取得
• 戦略分析と提言

第13章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET RESEARCH PROCESS
• FIGURE 2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET DYNAMICS
• FIGURE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN (IVIG), BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN (IVIG), BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY BLOOD & URINE TESTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY BLOOD & URINE TESTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ELECTRODIAGNOSTIC TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ELECTRODIAGNOSTIC TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 34. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 37. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 38. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 39. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 40. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 41. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 42. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 43. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 44. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 45. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 46. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 47. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 48. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 49. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 50. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 51. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 52. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 53. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 54. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 55. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 56. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 57. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 58. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 59. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 60. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 61. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 62. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 63. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 64. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 65. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 66. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 67. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 68. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 69. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 70. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 71. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 72. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 74. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 76. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 78. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 80. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 81. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 82. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 83. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 84. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 85. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 86. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 87. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 88. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 89. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 90. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 91. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 92. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 93. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 94. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 95. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 96. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 97. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 98. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 99. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 100. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 101. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 102. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 103. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 104. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 105. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 106. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 107. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 108. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 109. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 110. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 111. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 112. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 113. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 114. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 115. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 116. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 117. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 118. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 119. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 120. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 121. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 122. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 123. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 124. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 125. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 126. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 127. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 128. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 130. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 132. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 134. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 135. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 136. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 137. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 138. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 139. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 140. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 141. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 142. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 143. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 144. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 145. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 146. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 147. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 148. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 149. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 150. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 151. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 152. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 161. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 162. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 163. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 164. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 165. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 166. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 167. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 168. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 169. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 170. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 171. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 172. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 173. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 174. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 175. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 176. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 177. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 178. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 179. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 180. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 181. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 182. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 183. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 184. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 185. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 186. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 187. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 188. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 189. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 190. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 191. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 192. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 193. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 194. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 195. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 196. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 197. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 198. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 199. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 200. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 201. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 202. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 203. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 204. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 205. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 206. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 207. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 208. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 209. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 210. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 211. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 212. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 213. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 214. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 215. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 216. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 217. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 218. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 219. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 220. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 221. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 222. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 223. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 224. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 225. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 226. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 227. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 228. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 229. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 230. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 231. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 232. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 233. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 234. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 235. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 236. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 237. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 238. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 240. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 242. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 244. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 246. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 248. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 250. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 251. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 252. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 253. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 254. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 255. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 256. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 257. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 258. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 259. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 260. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 261. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 262. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 263. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 264. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 265. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
• TABLE 266. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
• TABLE 267. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 268. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 269. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 270. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 271. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET S

[187 Pages Report] The Chronic Inflammatory Demyelinating Polyneuropathy Market size was estimated at USD 2.35 billion in 2023 and expected to reach USD 2.49 billion in 2024, at a CAGR 5.81% to reach USD 3.49 billion by 2030.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neuromuscular or autoimmune disorder categorized by impaired sensory function in the legs and arms. The condition stems from the immune system mistakenly attacking the protective covering of the nerves, also known as the myelin sheath. This leads to slow nerve signal conduction, causing muscle weakness, reflex loss, and sensory problems. CIDP is paramount in neurology due to its chronic nature and significant impact on patient's quality of life. Rapid identification and appropriate therapeutic intervention are crucial in managing the symptoms and improving outcomes, highlighting the importance of ongoing research and development in treatments targeting this debilitating disorder. The rising concerns about neurological disorders and favorable government initiatives to support the treatment of these disorders propel the demand for CIDP treatment. However, the high cost associated with the CIDP is a significant challenge for the manufacturers and end users. Companies are constantly working towards research and development (R&D) and introducing novel drugs to remain agile within the landscape. Moreover, the Innovations in diagnostics and therapeutics for CIDP improve patient outcomes, thereby driving demand. Innovation and research include the development of more effective and less invasive treatment methods, novel diagnostic tools for early and accurate detection, and exploring the genetic basis of CIDP to uncover new therapeutic targets.

Treatment: Increasing usage of human intravenous immunoglobulin G in CIDP treatment to cater better patient outcomes

Chronic inflammatory demyelinating polyneuropathy (CIDP) management encompasses a holistic approach designed to dampen the improper immune reaction while enhancing the patient's quality of life. At the forefront of treatment protocols is administering intravenous immunoglobulin (IVIG), which supplies antibodies to adjust the immune system's functionality. Corticosteroids such as prednisone, which alleviate inflammation and modulate the immune system's vigor, are equally critical. Plasmapheresis represents an alternative strategy involving blood purification to eliminate deleterious antibodies for patients unresponsive to these treatments. Integral to the treatment regimen, physiotherapy aims to preserve and improve muscle strength, suppleness, and operational capacity, thereby playing an indispensable role in the comprehensive care approach for CIDP.

End-Use: Widening availability of CIDP treatment in hospitals and clinics to ensure broader accessibility to effective treatment regimens

Hospitals emerge as key facilities for initial diagnosis and treatment, providing comprehensive care, including intravenous immunoglobulin (IVIg) therapy, which demands specialized medical equipment and expertise. Specialty clinics offer a focused approach, catering to ongoing management and specialized treatments with professionals with in-depth knowledge of CIDP. Homecare settings are gaining prominence in maintaining the continuum of care, especially for long-term treatments, including subcutaneous immunoglobulin (SCIg) therapy, allowing patients comfort and convenience while minimizing hospital visits. Each of these settings offers distinct advantages and caters to the specific needs of the CIDP patient population, ensuring broader accessibility to effective treatment regimens.

Regional Insights

In the Americas, particularly the United States and Canada, there is a growing awareness and diagnosis rate of CIDP, driving demand for effective treatments. Patient-centric healthcare systems and high purchasing power produce strong customer purchasing behavior for innovative therapies. Significant R&D investments, coupled with favorable healthcare policies, support the growth of the CIDP market. Recent FDA approvals for CIDP treatments underscore the region's commitment to addressing this debilitating condition. On the other hand, European Union (EU) countries show a diverse landscape regarding CIDP awareness, diagnosis, and treatment access. Healthcare systems in the EU prioritize equitable access, with various countries adopting different models, including CIDP, to support rare disease treatments. Recent EU-wide initiatives focus on enhancing research, streamlining regulatory pathways, and fostering cross-border healthcare cooperation, aiming to improve patient outcomes across the continent. Asia Pacific countries such as China, Japan, and India are rapidly evolving in the CIDP market space, driven by increasing healthcare spending and improving diagnostic capabilities. Japan is in the region with advanced healthcare technologies and a strong focus on research, demonstrated by the high volume of patents and clinical trials. China and India are significant markets due to their large populations and growing awareness of autoimmune diseases, including CIDP.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Chronic Inflammatory Demyelinating Polyneuropathy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Chronic Inflammatory Demyelinating Polyneuropathy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Chronic Inflammatory Demyelinating Polyneuropathy Market, highlighting leading vendors and their innovative profiles. These include Avalon Pharma Pvt Ltd., Baxter International, Inc., Biotest AG, CSL Limited, F. Hoffmann-La Roche Ltd., Green Cross Corporation, Grifols, S.A., Johnson & Johnson Services, Inc., Kedrion Biopharma, Lee BioSolutions, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Viatris Inc., and Zai Lab Limited.

Market Segmentation & Coverage

This research report categorizes the Chronic Inflammatory Demyelinating Polyneuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Treatment
  • Corticosteroids
  • Intravenous Immunoglobulin (IVIG)
  • Physiotherapy
  • Plasmapheresis

• Diagnosis
  • Blood & Urine Tests
  • Electrodiagnostic Testing
  • Lumbar Puncture

• End-Use
  • Homecare Settings
  • Hospitals
  • Specialty Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Chronic Inflammatory Demyelinating Polyneuropathy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Chronic Inflammatory Demyelinating Polyneuropathy Market?

3. What are the technology trends and regulatory frameworks in the Chronic Inflammatory Demyelinating Polyneuropathy Market?

4. What is the market share of the leading vendors in the Chronic Inflammatory Demyelinating Polyneuropathy Market?

5. Which modes and strategic moves are suitable for entering the Chronic Inflammatory Demyelinating Polyneuropathy Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing concerns for autoimmune and neurological disorders worldwide
    • 5.1.1.2. Higher healthcare expenditure and insurance coverage for rare diseases
    • 5.1.1.3. Favorable government initiatives and approvals for CIDP treatment
  • 5.1.2. Restraints
    • 5.1.2.1. The high cost associated with CIDP treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research into understanding the pathophysiology of CIDP and the development of new treatments
    • 5.1.3.2. Continuous innovations in diagnostics and therapeutics for CIDP to improve patient outcomes
  • 5.1.4. Challenges
    • 5.1.4.1. Misdiagnosis or delayed diagnosis due to symptom similarity with other neuromuscular disorders
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment: Increasing usage of human intravenous immunoglobulin G in CIDP treatment to cater better patient outcomes
  • 5.2.2. End-Use: Widening availability of CIDP treatment in hospitals and clinics to ensure broader accessibility to effective treatment regimens
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment

• 6.1. Introduction
• 6.2. Corticosteroids
• 6.3. Intravenous Immunoglobulin (IVIG)
• 6.4. Physiotherapy
• 6.5. Plasmapheresis

7. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Diagnosis

• 7.1. Introduction
• 7.2. Blood & Urine Tests
• 7.3. Electrodiagnostic Testing
• 7.4. Lumbar Puncture

8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End-Use

• 8.1. Introduction
• 8.2. Homecare Settings
• 8.3. Hospitals
• 8.4. Specialty Clinics

9. Americas Chronic Inflammatory Demyelinating Polyneuropathy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Takeda's HYQVIA Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • 12.3.2. Takeda's HYQVIA Wins FDA Approval for CIDP Therapy
  • 12.3.3. Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio